Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fitbits and glucose monitors tested for exercise tracking in cancer and diabetes patients

NCT ID NCT05124405

Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether people with cancer or diabetes can use a Fitbit and a continuous glucose monitor (CGM) to track their daily exercise and glucose levels. The goal is to see if it's practical and if people will stick with it. Thirty-five participants will wear both devices for a period of time, and researchers will measure how many people agree to join and how well they follow the monitoring plan.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fitbit and continuous glucose monitor (CGM)
What this could lead to
If successful, this could show that wearable devices are a practical way to monitor physical activity and glucose levels in people with cancer or diabetes.
What could go wrong
This is a very small feasibility study with only 35 participants. It is not designed to test health outcomes, only whether people will use the devices as instructed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

May 2018

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women at least 18 years old * Body mass index (BMI) 25 kg/m2 * Engage in less than 150 minutes of moderate-intensity PA per week in the past month * Capable of participating in moderate-vigorous unsupervised exercise (as determined by the Physical Activity Readiness Questionnaire (PARQ) or a medical release from their physician) * Self-reported ability to walk one block without pain or discomfort * Have a smart phone with daily internet access that is compatible with the LibreLink app * Ability to speak, read, and write in English * For the cancer survivor cohort (participant accession number #21 and beyond), individuals must have been diagnosed with stage I-III breast or colorectal cancer and completed adjuvant therapy (i.e., chemo and/or radiation therapy). Exclusion Criteria: * Self-reported current diagnosis or history of type 1 diabetes or type 2 diabetes * Self-reported use of oral antidiabetic agents (OADs) * Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator) * Current use of a continuous glucose monitor * Fasting glucose \> 125 mg/dL * Pregnancy * Self-reported health issues that limit physical activity * On dialysis * Work overnight shifts * Unwilling to use CGM * Current participation in other wellness or weight loss-related program or intervention * Currently on a low-carb diet * Unable to receive REDCap survey through their mobile phones

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer cancer colorectal cancer diabetes mellitus neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Diabetes

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.